# Axonics Modulation Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axonics-modulation-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.axonics.com/
- Total disclosed funding: $87M
- Latest round: Series C (Jul 6, 2017)
- Investors on record: 6

## About

Founded in 2013 by co-founders Guangqiang Jiang and Raymond W. Cohen and based in California, US, Axonics Modulation Technologies, Inc. develops a rechargeable neuromodulation platform for the treatment of urinary and fecal dysfunction. In January 2024, Boston Scientific Corporation agreed to acquire Axonics Modulation Technologies, Inc. for USD 71 per share. The acquisition valued Axonics Modulation Technologies, Inc. at around USD 3.7 billion post-money. The transaction was completed in November 2024.

Axonics' core offering is the Axonics Therapy system, a minimally invasive treatment that leverages sacral neuromodulation (SNM) technology. SNM therapy involves implanting a medical device that delivers mild electrical pulses to the sacral nerves, which helps in regulating bladder and bowel function. This approach improves symptoms for patients struggling with conditions like overactive bladder, fecal incontinence, and non-obstructive urinary retention. The Axonics implant is MRI-safe, allowing patients to undergo magnetic resonance imaging scans without complications.

## Funding rounds

- Series C, Jul 6, 2017, $21M — Gilde Healthcare, Cormorant Asset Management
- Series C, May 2, 2017, $15M — Andera Partners, Legend Capital, NeoMed, Cormorant Asset Management, Advent Life Sciences
- Series B, Dec 21, 2015, $39M — Andera Partners, Legend Capital, NeoMed, Cormorant Asset Management, Advent Life Sciences
- Series A, Mar 14, 2014, $14M — Andera Partners, Legend Capital, NeoMed

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A, Series B, Series C
- Legend Capital — Series A, Series B, Series C
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series A, Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B, Series C
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series C